EUVIMEDEUVIMED entdecken
Open Access

Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes

Serina Tokita iD, Minami Fusagawa, Satoru Matsumoto, Tasuku Mariya iD, Mina Umemoto iD, Yoshihiko Hirohashi iD, Fumitake Hata, Tsuyoshi Saito iD, Takayuki Kanaseki iD, Toshihiko Torigoe iD

Science Advances · 20.09.2024 · 10 (38)

DOI: 10.1126/sciadv.ado6491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 20.09.2024. Verfasst von Serina Tokita und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Sapporo Medical University, Sapporo, Japan. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Histocompatibility Antigens Class I, Histocompatibility Antigens Class II. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoantigens arising from somatic mutations are tumor specific and induce antitumor host T cell responses. However, their sequences are individual specific and need to be identified for each patient for therapeutic applications. Here, we present a proteogenomic approach for neoantigen identification, named Neoantigen Selection using a Surrogate Immunopeptidome (NESSIE). This approach uses an autologous wild-type immunopeptidome as a surrogate for the tumor immunopeptidome and allows human leukocyte antigen (HLA)–agnostic identification of both HLA class I (HLA-I) and HLA class II (HLA-II) neoantigens. We demonstrate the direct identification of highly immunogenic HLA-I and HLA-II neoantigens using NESSIE in patients with colorectal cancer and endometrial cancer. Fresh or frozen tumor samples are not required for analysis, making it applicable to many patients in clinical settings. We also demonstrate tumor prevention by vaccination with selected neoantigens in a preclinical mouse model. This approach may benefit personalized T cell–mediated immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHumansAnimalsMiceFemaleCancer VaccinesColorectal NeoplasmsPeptidesEndometrial NeoplasmsImmunotherapy

Substanzen

Antigens, NeoplasmHistocompatibility Antigens Class IHistocompatibility Antigens Class IICancer VaccinesPeptides

Autor:innen und Institutionen

  • Department of Pathology, Sapporo Medical University, Sapporo, Japan.
  • Joint Research Center for Immunoproteogenomics, Sapporo Medical University, Sapporo, Japan.
  • Department of Surgery, IMS Sapporo Digestive Disease Center General Hospital, Sapporo, Japan.
  • Department of Obstetrics and Gynecology, Sapporo Medical University, Sapporo, Japan.
  • Department of Surgery, Sapporo Dohto Hospital, Sapporo, Japan.

ORCID-Profile: Serina Tokita, Tasuku Mariya, Mina Umemoto, Yoshihiko Hirohashi, Tsuyoshi Saito, Takayuki Kanaseki, Toshihiko Torigoe

Zitieren

APA

Tokita, S., Fusagawa, M., Matsumoto, S., Mariya, T., Umemoto, M., Hirohashi, Y., Hata, F., Saito, T., Kanaseki, T., & Torigoe, T. (2024). Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes. Science Advances, 10(38). https://doi.org/10.1126/sciadv.ado6491

Vancouver

Tokita S, Fusagawa M, Matsumoto S, Mariya T, Umemoto M, Hirohashi Y, et al. Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes. Science Advances. 2024;10(38). doi:10.1126/sciadv.ado6491

BibTeX
@article{Tokita2024,
  author = {Tokita, Serina and Fusagawa, Minami and Matsumoto, Satoru and Mariya, Tasuku and Umemoto, Mina and Hirohashi, Yoshihiko and Hata, Fumitake and Saito, Tsuyoshi and Kanaseki, Takayuki and Torigoe, Toshihiko},
  title = {Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes},
  journal = {Science Advances},
  year = {2024},
  volume = {10},
  number = {38},
  doi = {10.1126/sciadv.ado6491}
}
Kostenlos starten →